AltPep Strengthens Advisory Board with Three Leading Experts in Alzheimer’s Disease and Neurodegenerative Disorders

“AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of three new Advisory Board members: Paul Aisen, M.D., Sam Gandy, M.D., Ph.D., and Charlie Glabe, Ph.D. The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders.

‘We are honored to have these esteemed and accomplished scientific and clinical leaders join AltPep’s Advisory Board,’ said Valerie Daggett, Ph.D., Founder and CEO of AltPep. ‘These individuals have each made foundational contributions to the field of neurodegenerative diseases. Their depth of expertise, together with the contributions of our current advisors, will be critical in advancing the development of our unique platform for early detection and treatment of Alzheimer’s disease and other amyloid diseases.’“

The Risk of AIRA

Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).

Valerie Daggett, PhD

Chief Executive Officer

Valerie, the CEO/Founder of AltPep and an Endowed Professor of Bioengineering at the University of Washington, has been a champion of groundbreaking research for over 30 years. Her inherent curiosity pushes her to uncover new ways of tackling problems in the field of amyloid diseases, where successes are few.  Her tenacity led to a revolutionary discovery of a protein structure that could dramatically change the diagnosis and treatment of Alzheimer’s disease and over 50 other amyloid diseases. At AltPep, Valerie leads a team of innovators who are developing this platform to make the early, pre-symptomatic diagnosis and treatment of amyloid diseases a reality. Valerie holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.